news
Nanohybrid drug delivery vehicle could help treat Alzheimer’s
The chitosan drug delivery vehicle could be used for administering polyphenol ellagic acid (EA), a potential antioxidant treatment for Alzheimer’s and Parkinson’s.
List view / Grid view
Alzheimer's
Filter the results
news
‘Super-human’ red blood cells could revolutionise drug delivery
Modified ‘super-human’ red blood cells containing therapeutic compounds have been developed by researchers as a novel form of drug delivery.
news
FDA sends warning letter to company illegally selling CBD products
A business selling unapproved products containing CBD has been sent a warning letter from the FDA and FTC for making unsubstantiated claims about their therapeutic properties.
article
Shehnaaz Suliman Theravance Biopharma: ‘Being a healer in the face of inequality’
As part of EPR’s Women Inspiring Pharma series, Shehnaaz Suliman, SVP, Business Development and Strategy, Theravance Biopharma talks to Science Editor Dr Zara Kassam about fighting for human rights, inequality and the challenges women face in their careers...
news
Can aspirin treat Alzheimer’s?
A study shows low-dose aspirin may aid removal of harmful amyloid plaque in the brain...
news
MRC secures £40million for UK Dementia Research Institute building
A landmark £40million has been awarded to the UK Dementia Research Institute, via the Medical Research Council, for a new iconic hub building at University College London...
news
3F4AP tracer can measure demyelination in multiple sclerosis
PET imaging may improve diagnosis and monitoring for MS patients...
news
Multi-million funding for cryo-EM to boost structural biology revolution
US science minister announce new multi-million-pound commitment to boost the burgeoning field of cryo-electron microscopy (cryo-EM) in the UK.
news
27 Phase III and 8 Phase II Alzheimer’s drugs on track to launch in next 5 years
Twenty-seven Alzheimer's drugs in Phase III clinical trials and eight drugs in Phase II clinical trials may launch in the next five years...
news
Study predicts 1.2 million people in UK will be living with dementia by 2040
By 2040, there will be over 1.2 million people living with dementia in England and Wales (an increase of 57% from 2016), due to increased life expectancy...
news
AstraZeneca and Lilly receive FDA Fast Track designation for AZD3293, an investigational treatment for early Alzheimer’s disease
23 August 2016 | By AstraZeneca
AstraZeneca and Eli Lilly and Company have received US FDA Fast Track designation for the development programme in Alzheimer’s disease for AZD3293, an oral beta secretase cleaving enzyme inhibitor currently in Phase III clinical trial.
news
FDA approves expanded label for Namzaric in Alzheimer’s disease
20 July 2016 | By Victoria White, Digital Content Producer
The US Food and Drug Administration (FDA) has approved an expanded label for Namzaric.
news
Trial of RVT-101 in Alzheimer’s disease starts at Plymouth Science Park
11 July 2016 | By Victoria White, Digital Content Producer
If approved, RVT-101 could be the first Alzheimer’s treatment in 14 years. The last drug to be approved to help improve cognition was Donepezil in 2002...
news
Investigational Alzheimer’s treatment Aducanumab accepted into EMA’s PRIME programme
2 June 2016 | By Victoria White, Digital Content Producer
PRIME aims to bring treatments to patients faster by enhancing the EMA’s support for the development of investigational medicines...
news
Phase II/III trial of AZD3293 in early Alzheimer’s disease to continue
8 April 2016 | By Victoria White
AstraZeneca and Lilly have announced that AMARANTH, a Phase II/III study of AZD3293 will continue into Phase III of the Phase II/III seamless trial...